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Enthusiasm has been tempered by poor engraftment, survival and differentiation of the injected adult stem cells.
The crucial challenge is identiﬁcation and selection of the most suitable stem cell type for cardiac regenerative
medicine. Human pluripotent stem cells (PSCs) have emerged as attractive cell source to obtain cardiomyocytes
(CMs), with potential applications, including drug discovery and toxicity screening, disease modelling and inno-
vative cell therapies. Lessons from embryology offered important insights into the development of stem cell-de-
rived CMs. However, the generation of a CM population, uniform in cardiac subtype, adult maturation and
functional properties, is highly recommended. Moreover, hurdles regarding tumorigenesis, graft cell death, im-
mune rejection and arrhythmogenesis need to be overcome in clinical practice. Herewe highlight the recent pro-
gression in PSC technologies for the regeneration of injured heart. We review novel strategies that might
overcome current obstacles in heart regenerative medicine, aiming at improving cell survival and functional in-
tegration after cell transplantation.Laboratory, StemCel
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Cardiovascular disorders remain the major cause of morbidity and
mortality throughout the world. Over the last decades, death rates
have even increased signiﬁcantly (Nichols et al., 2014; Go et al., 2014).
The heart, previously considered as a terminally differentiated organ
with no regenerative capacity in post-natal life, has been documented
to exhibit a limited degree of regeneration. As a consequence, the
human heart regeneration capacity is unable to counteract the severe
loss of heart muscle tissue during myocardial infarction (MI) or other
myocardial disorders. Heart transplantation is the standard therapy to
replace the injured heart. Several experimental studies and recent clin-
ical trials assumed that stem cell-based transplantation might be indi-
cated as an alternative and promising therapeutic strategy for heart
failure. Multiple candidate stem cell types, including pluripotent stem
cells (PSCs), have been evaluated in animal models and in clinical
human studies for their ability to regenerate cardiac damage and recon-
stitute the cardiomyocyte (CM) loss.
This reviewdescribes the current research status on cell transplanta-
tion in animal models and humans. We discuss various stem cell types
with cardiac regenerative potential in a clinically relevant setting, such
as human embryonic (ESCs) and induced pluripotent stem cells
(iPSCs), as well as adult stem cells derived from the bonemarrow, mes-
enchymal tissues and the heart. In addition, we summarise some chal-
lenges that need to be overcome, and the future directions of stem
cell-based therapies for in vivo cardiac regeneration.
2. Lessons From Embryonic Cardiac Development: Translating Em-
bryology to PSCs
The formation of the three developmental germ layers, known as ec-
toderm, mesoderm and endoderm, is one of the most important hall-
marks in embryogenesis. In the mouse, the early phase of gastrulation
is characterised by the generation of the primitive streak (PS) in the epi-
blast that ultimatelywill form the posterior endof the embryo (Tamand
Behringer, 1997). Uncommitted epiblast cells undergo epithelial-mes-
enchymal transition (EMT) and migrate through the PS to contribute
to the embryonic structures and, ﬁnally, egress either as mesoderm or
deﬁnitive endoderm derivatives (Fig. 1). Patterning in the PS is deﬁned
as anterior, mid and posterior regions with differential gene expression
proﬁles and developmental potential. The heart originates from the car-
diac mesoderm, which arises from the anterior PS. Brachyury (T)Fig. 1.Mouse gastrulation. Early primitive streak (PS) formation at 6.5 days after fertilisation. T
coexpresses Brachyury and Foxa2/Goosecoid. Epiblast cells enter the anterior PS (black arrows o(Herrmann and Kispert, 1994) and Mixl1 (Hart et al., 2002) are
expressed throughout the PS, while Foxa2 and Goosecoid are expressed
mainly in the anterior regions (Kinder et al., 2001) and HoxB1 and
Evx1 posterior (Forlani et al., 2003; Dush and Martin, 1992). The pat-
terning of distinct subpopulations of mesoderm and endoderm is not
random but seems to be a regulated temporal and spatial process.
Mobilised epiblast cells diffuse through the anterior parts of the PS
and generate cranial and cardiac mesoderm, and subsequently paraxial
and axialmesoderm. Epiblast cells,which cross themost anterior region
of the PS, derive deﬁnitive endoderm. Ectoderm develops also from the
epiblast anterior region, although without entering the PS.
During gastrulation, the temporal and spatial determination of cell
fates in different PS regions towards speciﬁc developmental lineages de-
pends on the signalling cues in the surrounding environment. Members
of the Transforming Growth Factor Beta (TGFβ) family (including BMP4
andNodal) (Hogan, 1996; Conlon et al., 1994) andWnt familymembers
(Yamaguchi, 2001) play an essential role. Moreover, germ layer forma-
tion is a dynamic process that is tightly regulated by the coordinated ac-
tivation and inhibition of BMP4, Activin/Nodal and Wnt signalling
pathways (Gadue et al., 2005).
The BMP4, Activin/Nodal andWnt signalling pathways are required
in establishing the cardiovascular system. Mouse and human PSCs rep-
resent distinct development stages, although the signalling pathways
regulating human PSC differentiation are comparable to pathways con-
trolling differentiation in mice. Knowledge, obtained from mouse em-
bryonic development studies, has been translated to in vitro
differentiation of human PSCs to improve their differentiation efﬁciency
towards CMs (Sumi et al., 2008). The Wnt/β-catenin pathway has a
stage-speciﬁc biphasic role in cardiomyogenesis. It is required formeso-
derm induction, whereas inhibition occurs during the speciﬁcation of
the cardiac progenitor phase (Naito et al., 2006). Stimulating mouse
and human PSCs with BMP4 alone or in combination with Activin/
Nodal induces BRACHYURY and MIXL1 expression and the subsequent
formation of KDR+ and PDGFR+ cardiac mesoderm (Laﬂamme et al.,
2007; Kattman et al., 2011). The heart originates from the lateral plate
mesoderm and develops in two distinct cardiomyogenesis waves from
the primary (PHF) and secondary heart ﬁeld (SHF). Both heart ﬁelds ex-
press KDR and the transcription factor NKX2.5, whereas the SHF is
marked selectively by the transcription factor ISL1. These markers are
useful to identify cardiac progenitor cells (CPCs) from PSCs. Finally,
the PHF gives rise to the left ventricle and both atria, while the SHF de-
velops into the right ventricle and outﬂow tract (Wu et al., 2006).he posterior region of the PS coexpresses Brachyury and HoxB1/Evx1. The anterior region
n top of the embryo) and generate cardiac mesoderm.
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Adult stem cells have cardiogenic differentiation capacity, and there-
fore present cardiac regenerative research focuses on developing stem
cell sources to repair injured heart muscles. Several preclinical and clin-
ical studies have been conducted, providing the pros and cons of various
adult stem cell types for therapeutic approaches, including skeletal
myoblasts, bone marrow-derived mononuclear cells (BMMNCs), mes-
enchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endo-
thelial progenitor cells (EPCs) and CPCs (Fig. 2). However, the ideal
stem cell has not yet emerged and a limited number of studies have
compared different stem cell types (Wollert and Drexler, 2005). Until
now, all of these cell types have been thoroughly tested in clinical trials
in the heart, except human ESCs and iPSCs.3.1. Human PSCs: ESCs and iPSCs
In 1998, Thomson and colleagues succeeded to isolate human ESCs
from the inner cell mass of blastocysts (Thomson et al., 1998). ESCs
are considered as a promising cell source to achieve cardiac regenera-
tion through CM replacement. They exhibit unlimited self-renewal
and can differentiate into any cell type present in the adult organism, in-
cluding CMs or CPCs (Hartman et al., 2016). The ﬁrst transplantation re-
ports of human ESC-derived CMs (ESC-CMs) into pigs and guinea pigs
have shown their potential to function as biological pacemakers in elec-
trophysiologically silenced or atrioventricular (AV) blocked hearts
(Kehat et al., 2004). One of the initial technical challenges in ESC differ-
entiation towards the cardiovascular lineages was to obtain a high puri-
ty and large yield of differentiated cells. However, as knowledge of the
mouse embryonic heart development increased, mouse and human
ESC-CM differentiation became more efﬁcient and reproducible by ma-
nipulating the cardiac speciﬁc signalling pathways (Sumi et al., 2008).
Various strategies, like specialised culturingmethods, genetic modiﬁca-
tions or treatmentswith biological and chemical factors, have been con-
ducted to enrich and purify homogeneous and functional ESC-CMs
(Schwach and Passier, 2016). Recently, human ESC-CMs, successfully
generated on a large scale, were able to engraft and repair damaged
heart tissue in a primate MI model (Chong et al., 2014). These results
seemed hopeful since only a few different cell types showed efﬁcacy
in large animal models. However, the clinical use of human ESC-CMs
has been hampered by crucial limitations, like potential tumorigenic
and immunogenic properties, genetic instability, aswell as ethical issues
(Robertson, 2001).Fig. 2. Potential cell sources for heart regeneration therapy. Embryonic (ESC) and induced plu
improve cardiac morphological and functional characteristics via differentiation towards car
paracrine effects.Because human ESCs are derived from the inner cell mass of pre-im-
plantation stage blastocysts, the ethical and legislative debate arose sur-
rounding the use of ESCs for research purposes (Thomson et al., 1998).
As a consequence, in 2006, Yamanaka and Takahashi developed a novel
method to induce a pluripotent state in mouse somatic cells, referred as
iPSCs, by introducing a deﬁned set of transcription factors through ret-
roviral transduction. The combination of transcription factors used for
cellular reprogramming is Krüppel-Like Factor 4 (Klf4), Sex Determin-
ing Region Y-Box 2 (Sox2), V-Myc Avian Myelocytomatosis Viral Onco-
gene Homolog (cMyc) and POU Class 5 Homeobox 1 (Oct3/4)
(Takahashi and Yamanaka, 2006). In 2007, iPSCs were generated from
human origin, using the same cocktail of transcription factors (KLF4,
SOX2, cMYC and OCT3/4) (Takahashi et al., 2007) or mediated via
SOX2, OCT3/4, Lin-28 Homolog A (LIN28) and Nanog Homeobox
(NANOG) (Yu et al., 2007). Like ESCs, iPSCs have wide differentiation
ability, giving rise to all the cell types of the three germ layers (Lee et
al., 2014). The cardiogenic potential of the iPSC population has been ex-
tensively studied with iPSCs derived from mice (Mauritz et al., 2008)
and human (Zhang et al., 2009). IPSCs have been found to differentiate
in vitro in CMs and other cardiovascular cells, such as smooth muscle
cells and endothelial cells. More interestingly, iPSCs administered to
the injured heart of mice differentiated and resembled a cardiac pheno-
type (Mauritz et al., 2011). Although iPSCs have several characteristics
in commonwith ESCs (Gherghiceanu et al., 2011), genome-wide analy-
ses revealed signiﬁcant differences between both cell types regarding
gene expression proﬁles, methylation signatures and microRNA pat-
terns (Chin et al., 2009). Moreover, iPSCs circumvent the ethical and al-
logeneic transplantation problems in cardiac regenerative therapy
(Table 1) (Takahashi et al., 2007; Yu et al., 2007).
3.2. Mesodermal iPSC-derived Progenitors
Several potential therapeutic applications of stem cells have been
advised or are already under investigation in clinical trials. Stem cells,
including PSCs, could be used to generate in vitro tissues or artiﬁcial or-
gans for transplantation and to regenerate damaged tissue in vivo per se.
However, stem cell-derived artiﬁcial and functional organs are still far
from being realistic, the stem cell-based therapeutic approaches in re-
generative medicine and in hereditary diseases have already reached a
more advanced stage (Kimbrel and Lanza, 2015). Nowadays, several
groups are focusing on the development of strategies to target simulta-
neously multiple tissues to improve the treatment of hereditary disor-
ders. For example, muscular dystrophies (MDs) are monogenetic
disorders, in which chronic degeneration of both the skeletal andripotent stem cell (iPSC) populations as well as adult stem cell types have been shown to
diomyocytes (CMs), smooth muscle cells (SMCs) and endothelial cells (ECs) or through
Table 1
Characteristics of human adult and pluripotent stem cells.
Characteristics Adult stem cells Embryonic stem cells Induced pluripotent stem cells
Origin Found in postnatal tissues and organs Derived from embryos (inner cell mass of
blastocysts)
Derived from adult somatic cells
Ethics No ethical issues Ethical and legislative issues No ethical issues
Teratoma
formation
propensity
No teratoma risk Potential tumorigenic properties;
Puriﬁcation required before clinical use
Potential tumorigenic properties;
Puriﬁcation required before clinical use
Genetics and
immunogenicity
Genetic identity to patient;
Genetic stability and mild immune rejection;
Accumulation of mutations due to ageing
No genetic identity to patient;
Genetic instability and immune rejection
Genetic identity to patient;
Genetic instability and mild immune rejection;
Viral-based reprogramming may trigger antiviral
and anti-DNA antibody-mediated immunity
Cell availability Hard to access and advanced puriﬁcation
strategies needed;
Depends on differentiation efﬁciency
Depends on ethical issues;
Depends on differentiation efﬁciency
Depends on reprogramming efﬁciency;
Depends on differentiation efﬁciency
Differentiation
potential
Pluripotent or multipotent (depending of source
tissue);
Have restricted differentiation capacity
Pluripotent;
Give rise to derivatives of all three germ layers
Pluripotent;
Give rise to derivatives of all three germ layers;
“Epigenetic memory”
Cardiac
maturation
More mature ultrastructural phenotype,
electrophysiological functionality and
sarcoplasmic reticulum
Immature ultrastructural phenotype, immature
electrophysiological functionality and sarcoplasmic
reticulum
Immature ultrastructural phenotype and
electrophysiological functionality;
Evidence of more mature sarcoplasmic reticulum
Cardiac subtype
heterogeneity
Heterogeneous population of cardiomyocytes
with unclear paracrine or direct effects
Heterogeneous population of cardiomyocytes with
nodal-, atrial- and ventricular-like action potentials
Heterogeneous population of cardiomyocytes
with nodal-, atrial- and ventricular-like action
potentials
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get at the same time both striated muscle types would be a highly ap-
preciated and much-needed improvement for the treatment of MDs.
In this content, a novel iPSC-derived cell pool from mouse and human
origin was described, called mesodermal iPSC-derived progenitors
(MiPs), which were able to engraft into both skeletal and cardiac mus-
cles (Quattrocelli et al., 2015). MiPs were generated from ﬁbroblast-
and mesoangioblast (MAB)-derived iPSCs, showing a signiﬁcant higher
myogenic propensity compared to their ﬁbroblast-derived counterpart
due to their “epigenetic memory”. MiPs were amenable to gene correc-
tions and could restore muscle function in murine dystrophic models.
The in vivo regenerative potential of humanMiPs and their translational
applications for striated muscle repair were not yet fully addressed.
However, these preliminary results could pave the way for a combined
therapy for skeletal and cardiac muscles to treat MD patients.
4. Current Obstacles Towards Successful Therapeutic Applications
For optimal potential applications of human ESCs and iPSCs in car-
diovascular medicine, it is crucial to transplant highly pure human
PSC-CM populations, lacking undifferentiated PSCs. This circumvents
the PSC tumorigenicity and guarantees seamless integration of
transplanted cells for the uninterrupted cardiac function. It is also man-
datory to recapitulate the molecular, ultrastructural and electrophysio-
logical characteristics of these PSC-CMs in respect to CMs exhibiting an
adult phenotype (Table 1).
4.1. Teratomas and Karyotypic Abnormalities
A major concern that has to be taken into account in every clinical
therapy based on PSCs is their tendency to form tumours or teratomas.
Inefﬁcient differentiation or puriﬁcation techniques of undifferentiated
PSCs can cause undesirable tumours or teratomas after transplantation.
Still, several cardiac differentiation protocols deal with an unacceptable
amount of residual PSCs. Methods have been developed inwhich highly
puriﬁed CMs were generated from human PSCs (Xu et al., 2008). How-
ever, those methods are less clinically relevant because they introduce
genetic modiﬁcations in the cells. Last decades, various nongenetic CM
enrichment and isolation methods have been developed. Fluorescent-
activated cell sorting (FACS) based techniques, including mitochon-
dria-speciﬁc ﬂuorescent dyes (Hattori et al., 2010) or cardiac-speciﬁc
cell surface markers (like signal-regulatory protein alpha, SIRPA)(Dubois et al., 2011), are widely applied. Another nongenetic puriﬁca-
tionmethod for CMs derived fromPSCs is based on a differential glucose
and lactate metabolism among CMs and other cells, including undiffer-
entiated cells (Tohyama et al., 2013). These approaches yielded CMs of
99% purity and, more importantly, did not induce tumorigenesis after
transplantation. Nevertheless, none of these techniques is ideal for ther-
apeutic applications of human PSC-CMs because of insufﬁcient purity
and large-scale production for clinical use.
PSCs can show karyotypic instability with long-term culturing in
vitro, raising concerns about potential neoplastic transformation and
dysregulation of gene expression. Chromosomal abnormalities are high-
ly variable and depending on the cell line and culturing conditions
(Taapken et al., 2011).
4.2. Genetics and Immune Rejection
Autologous stem cell populations have a major advantage in cardio-
vascular medicine. Transplantation of (allogeneic) human ESC-CMs can
be identiﬁed as foreign, triggering an immune response. Therefore in
preclinical models, immunodeﬁcient or immunosuppressed animals
are used. Human iPSCs could have an important clinical advantage
over human ESCs because they can be created from the patient, leading
to genomematching iPSC-CMs. Surprisingly, studies reported that iPSCs
can still trigger an immune response, ascribed to the pluripotency
reprogramming procedure that induces both genetic and epigenetic de-
fects in iPSCs (Zhao et al., 2011; Lister et al., 2011).Most reprogramming
methods use viral components, which increase the risk of altering the
genome of the target cells, and triggering antiviral and anti-DNA anti-
body-mediated immunity (Kaneko and Yamanaka, 2013). Innovative
iPSC reprogramming techniques using nonviral vectors have been de-
veloped, such as microRNAs (Anokye-Danso et al., 2011; Miyoshi et
al., 2011) and small molecules accompanied with chemical compounds
(Zhu et al., 2010). In conclusion, nonviral and non-integrating
reprogramming techniques offer a better option for PSC-based therapy,
although mild immunogenicity can still occur due to culturing and dif-
ferentiation conditions, as well as epigenetic modiﬁcations.
4.3. Immature Phenotype
Molecular, ultrastructural and functional analyses of human PSC-
CMs revealed features of an early and immature phenotype. In terms
of morphology, spontaneous pacemaker activity, contractile apparatus
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dling properties, human PSCs have characteristics resembling fetal rath-
er than adult CMs (Karakikes et al., 2015). Before their clinical
application in cell-based therapies, the maturation phenotype of
human PSC-CMs must be addressed, since these de novo generated
CMs should replace the damaged heart tissue. In case the CM matura-
tion issue cannot be solved using the current available cardiac differen-
tiation protocols, alternative methods should be developed to enhance
maturation. Research groups are exploring the beneﬁcial effect on the
maturation of CMs mediated by electrical stimulation (Heidi Au et al.,
2009), cyclic stretch-induced mechanisms (Tulloch et al., 2011), chem-
ical manipulation (Pillekamp et al., 2012) and three-dimensional (3D)
tissue engineering techniques (Yang et al., 2014). Nowadays, robust
protocols to increase thematuration of human PSC-CMs are still lacking
and therefore, functional maturation is one of the critical obstacles to
overcome before PSC-CMs can be used for clinical applications.
4.4. Cardiomyocyte Subtype Heterogeneity
Currently available cardiac differentiation protocols from human
PSCs result usually in a heterogeneous pool of atrial-, ventricular- and
nodal-like CMs (Mummery et al., 2012). Recently published papers
have reported the importance of the exogenous addition of retinoic
acid (RA) (Zhang et al., 2011) and Wnt during human PSC differentia-
tion for cardiac chamber cell speciﬁcation. The administration of a
high percentage of nodal cells to a damaged heart increases the risk of
graft-associated arrhythmias. Treating differentiating human PSCs
with theWnt inhibitors, IWP and IWR-1, resulted in CMswith divergent
atrial and ventricular expression levels of respectivelyMLC-2a andMLC-
2v (Parikh et al., 2015). Inhibition of the Wnt signalling pathway by
using IWR-1 has been shown to differentiate human PSC-CMs towards
CM populations with mainly an atrial-like phenotype (Hudson et al.,
2012). However, conﬂicting data exists (Karakikes et al., 2014). Indeed,
human PSCs, subjected to an embryoid body (EB) based cardiac differ-
entiation protocol mediated by the Wnt inhibitor IWR-1, generated
more than 60% atrial-like CMs. By modulating the Activin signalling
pathway, the differentiation of human PSC-CMs was potentially
enriched in a ventricular-like adult phenotype (Duelen et al., 2017).
4.5. Scalability and Clinical Grade Production
The human adult heart consists of approximately 4 billion CMs, and
cardiovascular insults can lead to loss of cardiac tissue. For example,
after a typical MI up to 25% of CMs are lost, initiating progressive heart
failure (Caulﬁeld et al., 1976). Human PSC-CMs proliferate in vitro and
are highly expandable, making it reasonable to reconstitute the dam-
aged heart tissue, although signiﬁcantly high cell amounts are needed
for therapeutic goals. Recently, the feasibility to produce CMs and trans-
plant them on a large-scale has been demonstrated in a preclinical non-
human primate model (Chong et al., 2014). However, in this proof-of-
concept study the CM differentiation from PSCs was very labor-inten-
sive, expensive and clinically irrelevant (one-dozen 150 cm2 ﬂasks of
human PSC-CMs for each primate). Therefore, several groups use sus-
pension bioreactor-based culture systems to expand human PSCs and
differentiate towards very high quantities of CMs at purities up to 85%
(Kempf et al., 2014). Noteworthy, a decade ago it seemed unrealistic
to obtain such high quantities of human PSC-CMs.
5. Novel Strategies for Stem Cell-Based Therapies
Since the aforementioned obstacles are not yet completely over-
come, the development of novel strategies for stem cell therapies in car-
diac regeneration purposes remains the main focus. A successful stem
cell therapy for cardiac diseases depends on cell delivery routes. Deriv-
atives of PSCs can be systemically (intravenously or intracoronary) or
locally (intramyocardial injection) administered. Intravenous celldelivery is particularly appealing because of the ease of administration.
However, the major problem is the entrapment of the delivered cells in
the pulmonary microcirculation. Intravenous cell injections require ap-
propriate homing to the site of heart damage (Garbern and Lee, 2013).
In 2003, a pioneer study, in which radioactively labelled EPCs were in-
travenously delivered into a ratMImodel, showed a small portion of ra-
dioactivity (about 2%) in the heart after 24–96 h (Aicher et al., 2003).
Afterwards, these results have been conﬁrmed with the use of other
cells (Brenner et al., 2004; Nagaya et al., 2004). Intracoronary and
intramyocardial routes are relatively more complex compared to intra-
venous injections. The most common delivery route for cell therapy
after acute MI is the intracoronary route (Table 2). Main advantages in-
clude selective administration in the infarcted region and better uni-
form cell distribution in the target region. Intramyocardial injections
have been shown to be superior to intravenous and intracoronary injec-
tions regarding cell retention. There is no need for homing signals be-
cause cells are administered directly in the myocardium. Both delivery
routes have their limitations. The intracoronary injection demands a
transient ischemic period, detrimental for the heart, to get the optimal
distribution of the injected cells. While in an acute MI, the
intramyocardial injection could increase the risk for perforation due to
ischemia and necrosis (Hou et al., 2005). A comparative study of these
three delivery routes in a porcine MI model demonstrated that the en-
graftment of the transplanted cells within the infarct zone 14 days
after delivery was signiﬁcantly higher after intracoronary and
intramyocardial injections than intravenous administration, respective-
ly 106,000 ± 43,000 and 51,000 ± 24,000 cells/g in respect to the ab-
sence of MSCs in the infarct zone after intravenous injection (Freyman
et al., 2006). In the near future, the advance of transplantation tech-
niques might provide a more efﬁcient method for injected stem cells
to retain and survive in the damaged heart.
5.1. Combined Gene- and Cell-based Therapeutic Approaches
Cell therapy in combinationwith gene therapy raises the hope to in-
crease survival of transplanted cells by providing a continuous local de-
livery of targeted bioactivemediators. The growth of new blood vessels,
called angiogenesis, has become the main target of promoting long-
standing survival of injected cells. In addition, induced angiogenesis
could lead towards a better cardiac repair since functional regeneration
of the heart tissue requires a high metabolic activity, demanding sufﬁ-
cient blood supply (Fig. 3).
Cytokines and growth factors, known to induce angiogenesis, were
co-delivered into stem cells to increase the possibility for successful
and long-term engraftment in the heart. HGF- and VEGF-overexpress-
ing MSCs have been shown to promote revascularization and support
cardiac recovery after MI (Deuse et al., 2009). Furthermore, human
CD34+ haematopoietic stem cells genetically modiﬁed for the angio-
genic morphogen sonic hedgehog (Shh) protein showed preservation
of cardiac function after MI (Mackie et al., 2012). Recently, the oxy-
gen-sensitive transcription factor hypoxia-inducible factor-1 (HIF1)
co-delivered with injected CPCs into the ischemic myocardium has
been demonstrated to improve their survival (Ong and Hausenloy,
2012). Although the precise therapeutic mechanism of the co-delivered
angiogenic genes and proteins are not yet completely elucidated, it is
believed that they might improve survival or in vivo reprogramming
and proliferation of transplanted cells.
MicroRNAs, small (20–25 nucleotides) non-coding RNAs that regu-
late post-transcriptional gene expression, have become a new treat-
ment strategy with therapeutic evidence for MI. Several microRNAs
have been identiﬁed to improve CM survival. MicroRNA-126 overex-
pression in MSCs had beneﬁcial effects on their survival and migration,
and enhanced angiogenesis in the infarcted area, possibly due to stimu-
lation of the AKT/ERK-related pathway (Chen and Zhou, 2011), para-
crine effects (Huang et al., 2013) or either due to a combination. In
addition, overexpressed microRNA-155 prevented necrotic cell death
Table 2
Clinical trials of cell-based therapy after acute myocardial infarction.
Study name Design Cell type/dose (×108)
Route of
injection
Imaging
modalities
Cell delivery
after MI (days) Time follow-up/results Reference(s)
BOOST RCT Nucleated BM cells
24.6 ± 0.94
IC CMR, Echo 4–6
(STEMI)
6 months: improved EF
18 months: no improved EF, LV volumes and
RWM
5 years: no improved EF, LV volumes, infarct size
and RWM
Wollert et al. (2004)
Meyer et al. (2006,
2009)
/ RDBCT Nucleated BM cells
3 ± 1.28 (containing
1.72 ± 0.72 BMMNCs)
IC CMR 1–2 4 months: no improved EF, decreased infarct size,
increased RWM
12 months: no improved EF, LV volumes and
infarct size, increased RWM
Janssens et al. (2006)
ASTAMI RCT BMMNCs
0.7 (0.54–1.3)
IC SPECT, CMR,
Echo
4–8 6 months: no improved EF, LV volumes and infarct
size
12 months: no improved EF, LV volumes and
RWM
3 years: no improved EF, LV volumes, LV mass,
infarct zone and RWM
Lunde et al. (2006)
Lunde, and Aakhus
(2008)
Beitnes et al. (2009)
REPAIR-AMI RDBCT BMMNCs
2.36 ± 1.74
IC CMR, LV
angiography
3–6
(STEMI)
4 months: improved EF, ESV and RWM
1 year: decreased MACE, increased RWM
2 years: no improved EF and LV volumes,
decreased MACE and infarct size, increased RWM
5 years: decreased MACE
Schächinger et al.
(2006)
Assmus et al. (2010,
2014)
FINCELL RDBCT BMMNCs
0.04 ± 0.02
IC Echo, LV
angiography
2–6 6 months: no improved EF, improvement in ΔEF Huikuri et al. (2008)
REGENT RCT BMMNCs
1.78
CD34+CXCR4+
0.019
IC CMR, LV
angiography
3–12 6 months: no improved EF and LV volumes Tendera et al. (2009)
/ RDBCT Allogeneic BM MSCs
0.005, 0.016, 0.05/kg
IV CMR, Echo 1–10 6 months: no improved EF Hare et al. (2009)
TOPCARE-AMI RT Circulating progenitors
BMMNCs
IC CMR 3–7
(STEMI)
5 years: improved EF and decreased infarct size Leistner et al. (2011)
SCIPIO RCT CDCs
0.005–0. 01
IC CMR 113
(after CABG)
4 months: improved EF and decreased infarct size
12 months: improved EF and decreased infarct
size
Bolli et al. (2011)
TIME RDBCT BMMNCs
1.5
IC CMR 3–7 6 months: no improved EF, LV volumes, infarct
size and RWM
Traverse et al. (2012)
LateTIME RDBCT BMMNCs
1.5
IC CMR 15–20 6 months: no improved EF, LV volumes, infarct
size and RWM
Traverse et al. (2011)
APOLLO RDBCT ADRCs
0.17 ± 0.04
IC SPECT, CMR,
Echo
STEMI 6 months: no improved EF Houtgraaf et al. (2012)
CADUCEUS RCT CDCs
0.125–0.25
IC CMR 45–90 6 months: no improved EF, decreased scar mass
and increased RWM
12 months: no improved EF
Makkar et al. (2012)
SWISS-AMI RCT BMMNCs
1.4–1.6
IC CMR 5–7
21–28
4 months: no improved EF, LV volumes and scar
mass
Surder et al. (2013)
CELLWAVE RCT Shock wave
Pretreatment + BMMNCs
IC CMR, Echo,
LV
angiography
NA 4 months: improved EF, decreased infarct size and
increased RWM
Assmus et al. (2013)
ADRCs, autologous adipose tissue-derived regenerative cells; BM, bone marrow; BMMNCs, bone marrowmononuclear cells; CABG, coronary artery bypass grafting; CDCs, cardiosphere-
derived cells; CMR, cardiac magnetic resonance imaging; echo, echocardiography; EF, ejection fraction; ESV, end-systolic volume; IC, intracoronary; IV, intravenous; LV, left ventricular;
MACE, major adverse cardiovascular events, MSCs, mesenchymal stromal/stem cells; RT, randomized trial; RCT, randomized controlled trial; RDBCT, randomized double-blind controlled
trial; RWM, regional wall motion; SPECT, single-photon emission computed tomography; STEMI, ST-segment elevation acute myocardial infarction.
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2011). In contrast, several microRNAs, such as microRNA-15, -34, -140
and -320, negatively inﬂuenced CM survival and proliferation. As a con-
sequence, inhibiting these microRNAs promoted heart regeneration
(Boon and Dimmeler, 2015). Downregulation of microRNA-34 has
been determined to increase cell survival both in vitro and in vivo (Xu
et al., 2012). Overexpression of the cardiac enriched microRNA-133a
protected CPCs after MI by interfering with caspase 3 and proapoptotic
genes Bim and Bmf (Izarra et al., 2014). Interestingly, in vivomanipula-
tion of the microRNA machinery resulted in CM dedifferentiation and
improved heart functionality after injury (Eulalio et al., 2012; Aguirre
et al., 2014).
Despite a positive progression in the last years, it is still unclear
whether the myocardium regenerative ability of cytokines and growth
factors, and microRNAs could be translated to a clinical practice with a
comparable efﬁciency in human being as observed in experimental an-
imal models.5.2. Combined Cell- and Tissue-based Therapeutic Approaches
To counteract poor cell engraftment and survival of transplanted
cells, diverse biomaterials and tissue engineering techniques have re-
vealed promising results over the past decade. Two major strategies
are described in cardiac regeneration, namely cardiac patches and in-
jectable scaffolds, which support either endogenous repair and regener-
ation or act as vehicles to encourage cell delivery (Fig. 3).
Cardiac patches are in vitro engineered scaffolds of biomaterials to
deliver cells into the myocardium and to attract cells for endogenous
healing or to support the ventricle wall, maintaining its geometry dur-
ing remodelling. Approaches, in which biomaterials deliver stem cells
into the myocardium, have been reported to improve therapeutic ef-
fects after MI. Embedding cardiac stem cells (CSCs) within matrix-
enriched hydrogel capsules positively affected long-term cell survival,
retention and cardiac function in post-ischemic events (Mayﬁeld et al.,
2014). Natural biomaterials improve the mechanical strength of the
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growth factors. In a recent study, an IGF-1 microsphere-loaded ﬁbrin
patch, administered onto the epicardial surface of a porcine heart
post-MI, in combination with human iPSC-CMs, signiﬁcantly improved
survival and retention of the transplanted cells, and reduced ventricular
wall stress (Ye et al., 2014).
Engineered heart tissue (EHT) exhibits a potential cardiac restoration
function, demonstrating the integration of the implanted EHT with the
host heart and improving post-ischemic heart function. Zimmerman
and colleagues successfully developed large force-generating EHTs
from neonatal rat heart cells and, for the ﬁrst time, proved that these
large contractile EHT grafts could survive after implantation and result-
ed in a better functional outcome after MI (Zimmermann et al., 2002,
2006). Despite these promising results, the optimal maturation status
of EHTs before transplantation is still undetermined, and obtaining suf-
ﬁcient oxygen and nutrients supply through vascularization for CMs in
the EHTs is another remaining challenge.
Injectable scaffolds, another strategy combining biomaterials with
cells for transplantation, were examined in a ratMImodel by delivering
skeletal myoblasts with injectable ﬁbrin glue (Christman et al., 2004).
Biomaterials are produced from protein-based materials (Matrigel) to
synthetic materials (polyethylene glycol; PEG). Recently, injectable
scaffolds are used as drug-releasing systems for localised and sustained
secretion of growth factors, genes or small RNAs to promote cardiac
function and cell survival (Radisic and Christman, 2013). To date, di-
verse growth factors, like bFGF, HGF, IGF-1, PDGF, SDF-1, TGFβ1 and
VEGF, have been delivered. An innovative vector for tissue engineering,
called pharmacologically active microcarriers (PAMs), combines stem
cell therapy with drug-releasing systems. PAMs consist of growth fac-
tors and non-cytotoxic poly(lactic-co-glycolic acid) (PLGA) micro-
spheres covered with extracellular matrix (ECM) molecules (Giteau et
al., 2008). Injecting stem cells with VEGF-releasing PAMs provide a bio-
mimetic 3D microenvironment for the transplanted cells and enhance
their survival, differentiation and angiogenesis (Madonna et al., 2015).
Tissue engineering methods, combining stem cells with biomate-
rials, show optimistic perspectives for heart repair. However, advanced
progression in the ﬁeld demands a more multidisciplinary cooperation.
5.3. Stem Cell-derived Exosomes as Cell-free Alternative for Stem Cell-based
Cardiac Regeneration Therapy
Stem cell-conditioned medium has been documented to have bene-
ﬁcial effects on the injured heart, supporting the paracrine hypothesis
that formulates a chemical and physical signal mediated mode-of-ac-
tion. Indeed, different studies have proved that stem cells produce and
release a wide range of cytokines, growth factors and chemokines in-
volved in heart repair (Gnecchi et al., 2005; Takahashi et al., 2006). Fur-
thermore, stem cells have also the capacity to secrete membranous
vesicles (like microparticles, microvesicles and exosomes) into the ex-
tracellular space, contributing to intercellular communication (Chen et
al., 2010; Ratajczak et al., 2006; Sahoo et al., 2011) (Fig. 3).
Exosomes, extracellular membrane-bound vesicles with a diameter
typically ranging between 30 and 100 nm and released through the fu-
sion of multivesicular bodies with the plasma membrane (Thery et al.,
2002b), have been documented for the ﬁrst time in 2002 in dendritic
cells to be able to activate naïve CD4+ T cells (Thery et al., 2002a). An-
other landmark study validated exosomes as natural carriers of mRNA,
microRNA and proteins among cells (Valadi et al., 2007). Exosomes
have been demonstrated to exhibit cardioprotective functions by en-
hancing angiogenesis, decreasing ﬁbrotic tissue formation or reducing
apoptosis (Ibrahim et al., 2014). Therefore, exosomes could be used as
cell-free therapeutic candidates for heart regeneration. Mouse ESC-de-
rived exosomes (ESC-Exos) could enhance endogenous repair and pre-
served heart function in amouseMImodelmediated at least partially by
microRNA-294. Preserved heart functionwas associated with increased
angiogenesis, decreased apoptosis and enhanced CM proliferation. Inaddition, mouse ESC-Exos increased the number of proliferating CPCs
up to 4weeks post-MI (Khan et al., 2015). The Phase I completed CADU-
CEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventric-
Ular dySfunction; NCT00893360) trial have shown that it might be
possible that cardiosphere-derived cells (CDCs) regenerate damaged
heart muscles. The exact mechanism is unknown, although seemed to
be indirectly. Exosomes produced by CDCs were identiﬁed as keymedi-
ators of the CDC-induced regeneration. Moreover, CDC-derived
exosomes contained high amounts ofmicroRNA-146a, and selective ad-
ministration of microRNA-146a mimics some of the beneﬁcial effects of
CDC exosomes (Ibrahim et al., 2014). Based on these studies, a currently
recruiting Phase I/II clinical trial calledHOPE-Duchenne (Halt cardiomy-
OPathy progrEssion in Duchenne; NCT02485938) will assess the safety
and efﬁcacy of a multi-vessel intracoronary delivery of allogeneic CDCs
inMDpatientswith cardiomyopathy secondary to DuchenneMD. These
and other studies provided innovative insights for exosomes as cell-free
therapeutic candidates in heart regeneration instead of injected stem
cells, which were hampered by poor cell survival, teratomas formation,
as well as electric and mechanical coupling issues. Importantly, immu-
nogenicity concerns have to be addressed before exosomes will be
used in stem cell therapies. Although stem cell-derived exosomes are
less immunogenic than their parental cells, an inherent risk for an
exosome-triggered immune response in the infarcted myocardium
still exists. Exosome-mediated cardiac repair mechanisms are not yet
fully explored, but so far obtained results are encouraging.
6. Conclusions
Stem cell technology is undoubtedly the most attractive approach
for the generation of cardiac tissue and has been moved towards the
use of PSCs in the last few years. Adult stem cells, including skeletal
myoblasts,MSCs and cardiac stem cells were themost tested cell source
for cardiac regeneration in clinical trials as they have no ethical obstacle
and are non-tumorigenic. However, they exhibit limited self-renewal
and differentiation potential to become functional CMs. Experiments
in vitro but also in small and large animal models proved the
cardiomyogenic potential of PSC derivatives. SpeciﬁcmicroRNAs control
muscle progenitor proliferation and promote the differentiation of PSC-
derivedmuscle progenitors into CMs, wheremetabolic activity, survival
and remodelling process in response to stress are also ﬁne-tuned by
miRNAs. In this context, microRNA cargo within exosome-like vesicle
transfer is an intriguing possibility to burst the cardiomyogenic poten-
tial of progenitor cells in the diseased heart. It is an emerging fact that
exosome-microRNA technologies combined to stem cells could build
up unexplored therapeutic strategies for cardiac disorders. However, it
is crucial to better understand the basic principles of cardiac differenti-
ation of PSCs, including transcription factors, microRNA networks and
molecular pathways that contribute to CM maturation. Several chal-
lenges, including tumour formation, ethical and immunological con-
cerns, the optimal cardiac differentiation protocol, timing and delivery
route of stem cells remain to be overcome.
In addition, leading laboratories are investing in gene editing,mainly
in CRISPR/Cas9 technology, to successfully correct disease-causing al-
leles and PSCs are preferred since they can be easily expanded. These
novel approaches are raising hope for therapeutic genome editing of
cardiac genetic diseases in the clinics. Consequently, it is reasonable to
expect more and more combinations of PSC- and gene editing-based
therapies for cardiac genetic diseases.
The actual enormous costs of GLP-GMP (good laboratory andmanu-
facture practice) in PSC technology limit the feasibility of cell therapy
treatment. Strategies to lower costs are desirable to make PSC-based
treatments available for large numbers of patients. Despite a decade of
numerous clinical trials based on adult stem cell treatments with limit-
ed positive outcomes and encouraging results with PSC derivatives in a
preclinical setting, we are still in the infancy of a propitious cruise in the
ﬁeld of regenerative cardiac medicine.
Fig. 3. Stem cell-based strategies for cardiac regeneration after heart disease. Multiple techniques to improvemorphological and electromechanical properties of the diseased heart: (1) In
vitro cardiac differentiation of different stem cell types. (2) Tissue engineering approaches combining cells with biomaterials to design in vitro cardiac patches or injectable scaffolds for
transplantation into the infarcted heart area. (3) Cell- and gene-based strategies secreting cytokines, growth factors and microRNAs to promote cardiac regeneration. (4) Stem-cell
derived exosomes as an innovative cell-free therapy in heart regenerative medicine.
37R. Duelen, M. Sampaolesi / EBioMedicine 16 (2017) 30–40Acknowledgements
We would like to apologise to all authors whose work has not been
reported here due to space limitations. This work has been supported
with the contribution of “Opening The Future” Campaign [EJJ-OPTFUT-
02010] CARIPLO 2015_0634, FWO (#G088715N, #G060612N,
#G0A8813N), GOA (EJJ-C2161-GOA/11/012), IUAP-VII/07 (EJJ-C4851-
17/07-P), OT#09-053 (EJJ-C0420-OT/09/053) and Project Financiering
Stem Cells (PFO3 10/019) grants. We would also like to thank
Rondoufonds voor Duchenne Onderzoek (EQQ-FODUCH-O2010) for
kind donations.
References
Aguirre, A., Montserrat, N., Zacchigna, S., Nivet, E., Hishida, T., Krause, M.N., Kurian, L.,
Ocampo, A., Vazquez-Ferrer, E., Rodriguez-Esteban, C., Kumar, S., Moresco, J.J., Yates
3rd, J.R., Campistol, J.M., Sancho-Martinez, I., Giacca, M., Izpisua Belmonte, J.C., 2014.
In vivo activation of a conserved microRNA program induces mammalian heart re-
generation. Cell Stem Cell 15, 589–604.
Aicher, A., Brenner, W., Zuhayra, M., Badorff, C., Massoudi, S., Assmus, B., Eckey, T., Henze,
E., Zeiher, A.M., Dimmeler, S., 2003. Assessment of the tissue distribution of
transplanted human endothelial progenitor cells by radioactive labeling. Circulation
107, 2134–2139.
Anokye-Danso, F., Trivedi, C.M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., Yang, W.,
Gruber, P.J., Epstein, J.A., Morrisey, E.E., 2011. Highly efﬁcient miRNA-mediated
reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell
8, 376–388.
Assmus, B., Rolf, A., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Tillmanns, H., Yu,
J., Corti, R., Mathey, D.G., Hamm, C.W., Suselbeck, T., Tonn, T., Dimmeler, S., Dill, T.,
Zeiher, A.M., Schachinger, V., Investigators, R.-A., 2010. Clinical outcome 2 years
after intracoronary administration of bone marrow-derived progenitor cells in
acute myocardial infarction. Circ. Heart Fail. 3, 89–96.
Assmus, B., Walter, D.H., Seeger, F.H., Leistner, D.M., Steiner, J., Ziegler, I., Lutz, A., Khaled,
W., Klotsche, J., Tonn, T., Dimmeler, S., Zeiher, A.M., 2013. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure:
the CELLWAVE randomized clinical trial. JAMA 309, 1622–1631.
Assmus, B., Leistner, D.M., Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W.,
Hambrecht, R., Sedding, D., Yu, J., Corti, R., Mathey, D.G., Barth, C., Mayer-
Wehrstein, C., Burck, I., Sueselbeck, T., Dill, T., Hamm, C.W., Tonn, T., Dimmeler, S.,
Zeiher, A.M., Group, R.A.S., 2014. Long-term clinical outcome after intracoronary ap-
plication of bone marrow-derived mononuclear cells for acute myocardial infarction:
migratory capacity of administered cells determines event-free survival. Eur. Heart J.
35, 1275–1283.
Beitnes, J.O., Hopp, E., Lunde, K., Solheim, S., Arnesen, H., Brinchmann, J.E., Forfang, K.,
Aakhus, S., 2009. Long-term results after intracoronary injection of autologousmono-
nuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised,
controlled study. Heart 95, 1983–1989.
Bolli, R., Chugh, A.R., D'amario, D., Loughran, J.H., Stoddard, M.F., Ikram, S., Beache, G.M.,
Wagner, S.G., Leri, A., Hosoda, T., Sanada, F., Elmore, J.B., Goichberg, P., Cappetta, D.,
Solankhi, N.K., Fahsah, I., Rokosh, D.G., Slaughter, M.S., Kajstura, J., Anversa, P., 2011.
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results
of a randomised phase 1 trial. Lancet 378, 1847–1857.
Boon, R.A., Dimmeler, S., 2015. MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 12,
135–142.
Brenner, W., Aicher, A., Eckey, T., Massoudi, S., Zuhayra, M., Koehl, U., Heeschen, C.,
Kampen, W.U., Zeiher, A.M., Dimmeler, S., Henze, E., 2004. 111In-labeled CD34+ he-
matopoietic progenitor cells in a rat myocardial infarction model. J. Nucl. Med. 45,
512–518.
Caulﬁeld, J.B., Leinbach, R., Gold, H., 1976. The relationship of myocardial infarct size and
prognosis. Circulation 53, I141–I144.
Chen, J.J., Zhou, S.H., 2011. Mesenchymal stem cells overexpressing MiR-126 enhance is-
chemic angiogenesis via the AKT/ERK-related pathway. Cartogr. J. 18, 675–681.
Chen, T.S., Lai, R.C., Lee, M.M., Choo, A.B., Lee, C.N., Lim, S.K., 2010. Mesenchymal stem cell
secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 38, 215–224.
Chin, M.H., Mason, M.J., Xie, W., Volinia, S., Singer, M., Peterson, C., Ambartsumyan,
G., Aimiuwu, O., Richter, L., Zhang, J., Khvorostov, I., Ott, V., Grunstein, M.,
Lavon, N., Benvenisty, N., Croce, C.M., Clark, A.T., Baxter, T., Pyle, A.D., Teitell,
M.A., Pelegrini, M., Plath, K., Lowry, W.E., 2009. Induced pluripotent stem cells
and embryonic stem cells are distinguished by gene expression signatures. Cell
Stem Cell 5, 111–123.
Chong, J.J., Yang, X., Don, C.W., Minami, E., Liu, Y.W., Weyers, J.J., Mahoney, W.M., Van
Biber, B., Cook, S.M., Palpant, N.J., Gantz, J.A., Fugate, J.A., Muskheli, V., Gough, G.M.,
38 R. Duelen, M. Sampaolesi / EBioMedicine 16 (2017) 30–40Vogel, K.W., Astley, C.A., Hotchkiss, C.E., Baldessari, A., Pabon, L., Reinecke, H., Gill, E.A.,
Nelson, V., Kiem, H.P., Laﬂamme, M.A., Murry, C.E., 2014. Human embryonic-stem-
cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510,
273–277.
Christman, K.L., Vardanian, A.J., Fang, Q., Sievers, R.E., Fok, H.H., Lee, R.J., 2004. Injectable
ﬁbrin scaffold improves cell transplant survival, reduces infarct expansion, and in-
duces neovasculature formation in ischemic myocardium. J. Am. Coll. Cardiol. 44,
654–660.
Conlon, F.L., Lyons, K.M., Takaesu, N., Barth, K.S., Kispert, A., Herrmann, B., Robertson, E.J.,
1994. A primary requirement for nodal in the formation and maintenance of the
primitive streak in the mouse. Development 120, 1919–1928.
Deuse, T., Peter, C., Fedak, P.W., Doyle, T., Reichenspurner, H., Zimmermann, W.H.,
Eschenhagen, T., Stein, W., Wu, J.C., Robbins, R.C., Schrepfer, S., 2009. Hepatocyte
growth factor or vascular endothelial growth factor gene transfer maximizes mesen-
chymal stem cell-basedmyocardial salvage after acute myocardial infarction. Circula-
tion 120, S247–S254.
Dubois, N.C., Craft, A.M., Sharma, P., Elliott, D.A., Stanley, E.G., Elefanty, A.G., Gramolini, A.,
Keller, G., 2011. SIRPA is a speciﬁc cell-surface marker for isolating cardiomyocytes
derived from human pluripotent stem cells. Nat. Biotechnol. 29, 1011–1018.
Duelen, R., Gilbert, G., Patel, A., de Schaetzen, N., De Waele, L., Roderick, L., Sipido, K.R.,
Verfaillie, C.M., Buyse, G.M., Thorrez, L., Sampaolesi, M., 2017. Activin A modulates
CRIPTO-1/HNF4α+ cells to guide cardiac differentiation from human embryonic
stem cells. Stem Cells Int. 2017, 17.
Dush, M.K., Martin, G.R., 1992. Analysis of mouse Evx genes: Evx-1 displays graded ex-
pression in the primitive streak. Dev. Biol. 151, 273–287.
Emery, A.E., 2002. The muscular dystrophies. Lancet 359, 687–695.
Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S., Giacca, M., 2012.
Functional screening identiﬁes miRNAs inducing cardiac regeneration. Nature 492,
376–381.
Forlani, S., Lawson, K.A., Deschamps, J., 2003. Acquisition of Hox codes during gastrulation
and axial elongation in the mouse embryo. Development 130, 3807–3819.
Freyman, T., Polin, G., Osman, H., Crary, J., Lu, M., Cheng, L., Palasis, M., Wilensky, R.L.,
2006. A quantitative, randomized study evaluating three methods of mesenchymal
stem cell delivery following myocardial infarction. Eur. Heart J. 27, 1114–1122.
Gadue, P., Huber, T.L., Nostro, M.C., Kattman, S., Keller, G.M., 2005. Germ layer induction
from embryonic stem cells. Exp. Hematol. 33, 955–964.
Garbern, J.C., Lee, R.T., 2013. Cardiac stem cell therapy and the promise of heart regener-
ation. Cell Stem Cell 12, 689–698.
Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O., Popescu, L.M.,
2011. Cardiomyocytes derived from human embryonic and induced pluripotent stem
cells: comparative ultrastructure. J. Cell. Mol. Med. 15, 2539–2551.
Giteau, A., Venier-Julienne, M.C., Marchal, S., Courthaudon, J.L., Sergent, M., Montero-
Menei, C., Verdier, J.M., Benoit, J.P., 2008. Reversible protein precipitation to ensure
stability during encapsulation within PLGA microspheres. Eur. J. Pharm. Biopharm.
70, 127–136.
Gnecchi, M., He, H., Liang, O.D., Melo, L.G., Morello, F., Mu, H., Noiseux, N., Zhang, L.,
Pratt, R.E., Ingwall, J.S., Dzau, V.J., 2005. Paracrine action accounts for marked
protection of ischemic heart by Akt-modiﬁed mesenchymal stem cells. Nat.
Med. 11, 367–368.
Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Dai, S., Ford, E.S.,
Fox, C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M., Heit, J.A., Howard, V.J.,
Huffman, M.D., Judd, S.E., Kissela, B.M., Kittner, S.J., Lackland, D.T., Lichtman, J.H.,
Lisabeth, L.D., Mackey, R.H., Magid, D.J., Marcus, G.M., Marelli, A., Matchar, D.B.,
Mcguire, D.K., Mohler 3rd, E.R., Moy, C.S., Mussolino, M.E., Neumar, R.W., Nichol, G.,
Pandey, D.K., Paynter, N.P., Reeves, M.J., Sorlie, P.D., Stein, J., Towﬁghi, A., Turan,
T.N., Virani, S.S., Wong, N.D., Woo, D., Turner, M.B., American Heart Association
Statistics Committee, Stroke Statistics Subcommittee, 2014. Heart disease and stroke
statistics-2014 update: a report from the American Heart Association. Circulation
129, e28–e292.
Hare, J.M., Traverse, J.H., Henry, T.D., Dib, N., Strumpf, R.K., Schulman, S.P., Gerstenblith, G.,
Demaria, A.N., Denktas, A.E., Gammon, R.S., Hermiller Jr., J.B., Reisman, M.A., Schaer,
G.L., Sherman, W., 2009. A randomized, double-blind, placebo-controlled, dose-esca-
lation study of intravenous adult human mesenchymal stem cells (prochymal) after
acute myocardial infarction. J. Am. Coll. Cardiol. 54, 2277–2286.
Hart, A.H., Hartley, L., Sourris, K., Stadler, E.S., Li, R., Stanley, E.G., Tam, P.P., Elefanty, A.G.,
Robb, L., 2002. Mixl1 is required for axial mesendodermmorphogenesis and pattern-
ing in the murine embryo. Development 129, 3597–3608.
Hartman, M.E., Dai, D.F., Laﬂamme, M.A., 2016. Human pluripotent stem cells: prospects
and challenges as a source of cardiomyocytes for in vitro modeling and cell-based
cardiac repair. Adv. Drug Deliv. Rev. 96, 3–17.
Hattori, F., Chen, H., Yamashita, H., Tohyama, S., Satoh, Y.S., Yuasa, S., Li, W., Yamakawa, H.,
Tanaka, T., Onitsuka, T., Shimoji, K., Ohno, Y., Egashira, T., Kaneda, R., Murata, M.,
Hidaka, K., Morisaki, T., Sasaki, E., Suzuki, T., Sano, M., Makino, S., Oikawa, S.,
Fukuda, K., 2010. Nongenetic method for purifying stem cell-derived cardiomyocytes.
Nat. Methods 7, 61–66.
Heidi AU, H.T., Cui, B., Chu, Z.E., Veres, T., Radisic, M., 2009. Cell culture chips for simulta-
neous application of topographical and electrical cues enhance phenotype of
cardiomyocytes. Lab Chip 9, 564–575.
Herrmann, B.G., Kispert, A., 1994. The T genes in embryogenesis. Trends Genet. 10,
280–286.
Hogan, B.L., 1996. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev.
6, 432–438.
Hou, D., Youssef, E.A., Brinton, T.J., Zhang, P., Rogers, P., Price, E.T., Yeung, A.C., Johnstone,
B.H., Yock, P.G., March, K.L., 2005. Radiolabeled cell distribution after intramyocardial,
intracoronary, and interstitial retrograde coronary venous delivery: implications for
current clinical trials. Circulation 112, I150–I156.Houtgraaf, J.H., Den Dekker, W.K., Van Dalen, B.M., Springeling, T., De Jong, R., Van Geuns,
R.J., Geleijnse, M.L., Fernandez-Aviles, F., Zijlsta, F., Serruys, P.W., Duckers, H.J., 2012.
First experience in humans using adipose tissue-derived regenerative cells in the
treatment of patients with ST-segment elevation myocardial infarction. J. Am. Coll.
Cardiol. 59, 539–540.
Huang, F., Zhu, X., Hu, X.Q., Fang, Z.F., Tang, L., Lu, X.L., Zhou, S.H., 2013. Mesenchymal
stem cells modiﬁed with miR-126 release angiogenic factors and activate Notch li-
gand Delta-like-4, enhancing ischemic angiogenesis and cell survival. Int. J. Mol.
Med. 31, 484–492.
Hudson, J., Titmarsh, D., Hidalgo, A., Wolvetang, E., Cooper-White, J., 2012. Primitive car-
diac cells from human embryonic stem cells. Stem Cells Dev. 21, 1513–1523.
Huikuri, H.V., Kervinen, K., Niemela, M., Ylitalo, K., Saily, M., Koistinen, P., Savolainen, E.R.,
Ukkonen, H., Pietila, M., Airaksinen, J.K., Knuuti, J., Makikallio, T.H., Investigators, F.,
2008. Effects of intracoronary injection of mononuclear bone marrow cells on left
ventricular function, arrhythmia risk proﬁle, and restenosis after thrombolytic thera-
py of acute myocardial infarction. Eur. Heart J. 29, 2723–2732.
Ibrahim, A.G., Cheng, K., Marban, E., 2014. Exosomes as critical agents of cardiac regener-
ation triggered by cell therapy. Stem Cell Rep. 2, 606–619.
Izarra, A., Moscoso, I., Levent, E., Canon, S., Cerrada, I., Diez-Juan, A., Blanca, V., Nunez-Gil,
I.J., Valiente, I., Ruiz-Sauri, A., Sepulveda, P., Tiburcy, M., Zimmermann, W.H., Bernad,
A., 2014. miR-133a enhances the protective capacity of cardiac progenitors cells after
myocardial infarction. Stem Cell Rep. 3, 1029–1042.
Janssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., Desmet, W., Kalantzi, M.,
Herbots, L., Sinnaeve, P., Dens, J., Maertens, J., Rademakers, F., Dymarkowski, S.,
Gheysens, O., Van Cleemput, J., Bormans, G., Nuyts, J., Belmans, A., Mortelmans, L.,
Boogaerts, M., Van De Werf, F., 2006. Autologous bone marrow-derived stem-cell
transfer in patients with ST-segment elevation myocardial infarction: double-blind,
randomised controlled trial. Lancet 367, 113–121.
Kaneko, S., Yamanaka, S., 2013. To be immunogenic, or not to be: that's the iPSC question.
Cell Stem Cell 12, 385–386.
Karakikes, I., Senyei, G.D., Hansen, J., Kong, C.W., Azeloglu, E.U., Stillitano, F., Lieu, D.K.,
Wang, J., Ren, L., Hulot, J.S., Iyengar, R., Li, R.A., Hajjar, R.J., 2014. Small molecule-me-
diated directed differentiation of human embryonic stem cells toward ventricular
cardiomyocytes. Stem Cells Transl. Med. 3, 18–31.
Karakikes, I., Ameen, M., Termglinchan, V., Wu, J.C., 2015. Human induced pluripotent
stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional
phenotypes. Circ. Res. 117, 80–88.
Kattman, S.J., Witty, A.D., Gagliardi, M., Dubois, N.C., Niapour, M., Hotta, A., Ellis, J., Keller,
G., 2011. Stage-speciﬁc optimization of activin/nodal and BMP signaling promotes
cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem
Cell 8, 228–240.
Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., Huber, I., Satin, J.,
Itskovitz-Eldor, J., Gepstein, L., 2004. Electromechanical integration of cardiomyocytes
derived from human embryonic stem cells. Nat. Biotechnol. 22, 1282–1289.
Kempf, H., Olmer, R., Kropp, C., Ruckert, M., Jara-Avaca, M., Robles-Diaz, D., Franke, A.,
Elliott, D.A., Wojciechowski, D., Fischer, M., Roa Lara, A., Kensah, G., Gruh, I.,
Haverich, A., Martin, U., Zweigerdt, R., 2014. Controlling expansion and
cardiomyogenic differentiation of human pluripotent stem cells in scalable suspen-
sion culture. Stem Cell Rep. 3, 1132–1146.
Khan, M., Nickoloff, E., Abramova, T., Johnson, J., Verma, S.K., Krishnamurthy, P., Mackie,
A.R., Vaughan, E., Garikipati, V.N., Benedict, C., Ramirez, V., Lambers, E., Ito, A., Gao,
E., Misener, S., Luongo, T., Elrod, J., Qin, G., Houser, S.R., Koch, W.J., Kishore, R.,
2015. Embryonic stem cell-derived exosomes promote endogenous repair
mechanisms and enhance cardiac function following myocardial infarction. Circ.
Res. 117, 52–64.
Kimbrel, E.A., Lanza, R., 2015. Current status of pluripotent stem cells: moving the ﬁrst
therapies to the clinic. Nat. Rev. Drug Discov. 14, 681–692.
Kinder, S.J., Tsang, T.E., Wakamiya, M., Sasaki, H., Behringer, R.R., Nagy, A., Tam, P.P., 2001.
The organizer of the mouse gastrula is composed of a dynamic population of progen-
itor cells for the axial mesoderm. Development 128, 3623–3634.
Laﬂamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., Dupras, S.K.,
Reinecke, H., Xu, C., Hassanipour, M., Police, S., O'sullivan, C., Collins, L., Chen, Y.,
Minami, E., Gill, E.A., Ueno, S., Yuan, C., Gold, J., Murry, C.E., 2007. Cardiomyocytes de-
rived from human embryonic stem cells in pro-survival factors enhance function of
infarcted rat hearts. Nat. Biotechnol. 25, 1015–1024.
Lee, J.H., Lee, J.B., Shapovalova, Z., Fiebig-Comyn, A., Mitchell, R.R., Laronde, S., Szabo, E.,
Benoit, Y.D., Bhatia, M., 2014. Somatic transcriptome priming gates lineage-speciﬁc
differentiation potential of human-induced pluripotent stem cell states. Nat.
Commun. 5, 5605.
Leistner, D.M., Fischer-Rasokat, U., Honold, J., Seeger, F.H., Schachinger, V., Lehmann, R.,
Martin, H., Burck, I., Urbich, C., Dimmeler, S., Zeiher, A.M., Assmus, B., 2011. Trans-
plantation of progenitor cells and regeneration enhancement in acute myocardial in-
farction (TOPCARE-AMI): ﬁnal 5-year results suggest long-term safety and efﬁcacy.
Clin. Res. Cardiol. 100, 925–934.
Lister, R., Pelizzola, M., Kida, Y.S., Hawkins, R.D., Nery, J.R., Hon, G., Antosiewicz-Bourget, J.,
O'malley, R., Castanon, R., Klugman, S., Downes, M., Yu, R., Stewart, R., Ren, B.,
Thomson, J.A., Evans, R.M., Ecker, J.R., 2011. Hotspots of aberrant epigenomic
reprogramming in human induced pluripotent stem cells. Nature 471, 68–73.
Liu, J., Van Mil, A., Vrijsen, K., Zhao, J., Gao, L., Metz, C.H., Goumans, M.J., Doevendans, P.A.,
Sluijter, J.P., 2011. MicroRNA-155 prevents necrotic cell death in human cardiomyo-
cyte progenitor cells via targeting RIP1. J. Cell. Mol. Med. 15, 1474–1482.
Lunde, K., Solheim, S., Aakhus, S., Arnesen, H., Abdelnoor, M., Egeland, T., Endresen, K.,
Ilebekk, a., Mangschau, A., Fjeld, J.G., Smith, H.J., Taraldsrud, E., Grogaard, H.K.,
Bjornerheim, R., Brekke, M., Muller, C., Hopp, E., Ragnarsson, A., Brinchmann, J.E.,
Forfang, K., 2006. Intracoronary injection of mononuclear bone marrow cells in
acute myocardial infarction. N. Engl. J. Med. 355, 1199–1209.
39R. Duelen, M. Sampaolesi / EBioMedicine 16 (2017) 30–40Lunde, K., Aakhus, S., 2008. Cell therapy in acute myocardial infarction: measures of efﬁ-
cacy. Heart 94, 969–970.
Mackie, A.R., Klyachko, E., Thorne, T., Schultz, K.M., Millay, M., Ito, A., Kamide, C.E., Liu, T.,
Gupta, R., Sahoo, S., Misener, S., Kishore, R., Losordo, D.W., 2012. Sonic hedgehog-
modiﬁed human CD34+ cells preserve cardiac function after acute myocardial in-
farction. Circ. Res. 111, 312–321.
Madonna, R., Petrov, L., Teberino, M.A., Manzoli, L., Karam, J.P., Renna, F.V., Ferdinandy, P.,
Montero-Menei, C.N., Yla-Herttuala, S., De Caterina, R., 2015. Transplantation of adi-
pose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers pro-
motes repair in murine myocardial infarction. Cardiovasc. Res. 108, 39–49.
Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman, D., Czer, L.S.,
Marban, L., Mendizabal, A., Johnston, P.V., Russell, S.D., Schuleri, K.H., Lardo, A.C.,
Gerstenblith, G., Marban, E., 2012. Intracoronary cardiosphere-derived cells for
heart regeneration after myocardial infarction (CADUCEUS): a prospective,
randomised phase 1 trial. Lancet 379, 895–904.
Mauritz, C., Schwanke, K., Reppel, M., Neef, S., Katsirntaki, K., Maier, L.S., Nguemo, F.,
Menke, S., Haustein, M., Hescheler, J., Hasenfuss, G., Martin, U., 2008. Generation of
functional murine cardiac myocytes from induced pluripotent stem cells. Circulation
118, 507–517.
Mauritz, C., Martens, A., Rojas, S.V., Schnick, T., Rathert, C., Schecker, N., Menke, S., Glage,
S., Zweigerdt, R., Haverich, A., Martin, U., Kutschka, I., 2011. Induced pluripotent stem
cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart
function in a mouse model of acute myocardial infarction. Eur. Heart J. 32,
2634–2641.
Mayﬁeld, A.E., Tilokee, E.L., Latham, N., Mcneill, B., Lam, B.K., Ruel, M., Suuronen, E.J.,
Courtman, D.W., Stewart, D.J., Davis, D.R., 2014. The effect of encapsulation of cardiac
stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic
cell retention and cardiac function. Biomaterials 35, 133–142.
Meyer, G.P., Wollert, K.C., Lotz, J., Steffens, J., Lippolt, P., Fichtner, S., Hecker, H., Schaefer,
A., Arseniev, L., Hertenstein, B., Ganser, A., Drexler, H., 2006. Intracoronary bone mar-
row cell transfer after myocardial infarction: eighteen months' follow-up data from
the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation
infarct regeneration) trial. Circulation 113, 1287–1294.
Meyer, G.P., Wollert, K.C., Lotz, J., Pirr, J., Rager, U., Lippolt, P., Hahn, A., Fichtner, S.,
Schaefer, A., Arseniev, L., Ganser, A., Drexler, H., 2009. Intracoronary bone marrow
cell transfer after myocardial infarction: 5-year follow-up from the randomized-con-
trolled BOOST trial. Eur. Heart J. 30, 2978–2984.
Miyoshi, N., Ishii, H., Nagano, H., Haraguchi, N., Dewi, D.L., Kano, Y., Nishikawa, S.,
Tanemura, M., Mimori, K., Tanaka, F., Saito, T., Nishimura, J., Takemasa, I.,
Mizushima, T., Ikeda, M., Yamamoto, H., Sekimoto, M., Doki, Y., Mori, M., 2011.
Reprogramming of mouse and human cells to pluripotency using maturemicroRNAs.
Cell Stem Cell 8, 633–638.
Mummery, C.L., Zhang, J., Ng, E.S., Elliott, D.A., Elefanty, A.G., Kamp, T.J., 2012. Differentia-
tion of human embryonic stem cells and induced pluripotent stem cells to
cardiomyocytes: a methods overview. Circ. Res. 111, 344–358.
Nagaya, N., Fujii, T., Iwase, T., Ohgushi, H., Itoh, T., Uematsu, M., Yamagishi, M., Mori, H.,
Kangawa, K., Kitamura, S., 2004. Intravenous administration of mesenchymal stem
cells improves cardiac function in rats with acute myocardial infarction through an-
giogenesis and myogenesis. Am. J. Physiol. Heart Circ. Physiol. 287, H2670–H2676.
Naito, A.T., Shiojima, I., Akazawa, H., Hidaka, K., Morisaki, T., Kikuchi, A., Komuro, I., 2006.
Developmental stage-speciﬁc biphasic roles of Wnt/beta-catenin signaling in
cardiomyogenesis and hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 103, 19812–19817.
Nichols, M., Townsend, N., Scarborough, P., Rayner, M., 2014. Cardiovascular disease in
Europe 2014: epidemiological update. Eur. Heart J. 35, 2929.
Ong, S.G., Hausenloy, D.J., 2012. Hypoxia-inducible factor as a therapeutic target for
cardioprotection. Pharmacol. Ther. 136, 69–81.
Parikh, A., Wu, J., Blanton, R.M., Tzanakakis, E.S., 2015. Signaling pathways and gene regula-
tory networks in cardiomyocyte differentiation. Tissue Eng. Part B Rev. 21, 377–392.
Pillekamp, F., Haustein, M., Khalil, M., Emmelheinz, M., Nazzal, R., Adelmann, R., Nguemo,
F., Rubenchyk, O., Pfannkuche, K., Matzkies, M., Reppel, M., Bloch, W., Brockmeier, K.,
Hescheler, J., 2012. Contractile properties of early human embryonic stem cell-de-
rived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy
and lusitropy but not inotropy. Stem Cells Dev. 21, 2111–2121.
Quattrocelli, M., Swinnen, M., Giacomazzi, G., Camps, J., Barthelemy, I., Ceccarelli, G.,
Caluwe, E., Grosemans, H., Thorrez, L., Pelizzo, G., Muijtjens, M., Verfaillie, C.M., Blot,
S., Janssens, S., Sampaolesi, M., 2015. Mesodermal iPSC-derived progenitor cells func-
tionally regenerate cardiac and skeletal muscle. J. Clin. Invest. 125, 4463–4482.
Radisic, M., Christman, K.L., 2013. Materials science and tissue engineering: repairing the
heart. Mayo Clin. Proc. 88, 884–898.
Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., Ratajczak, M.Z., 2006. Em-
bryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evi-
dence for horizontal transfer of mRNA and protein delivery. Leukemia 20, 847–856.
Robertson, J.A., 2001. Human embryonic stem cell research: ethical and legal issues. Nat.
Rev. Genet. 2, 74–78.
Sahoo, S., Klychko, E., Thorne, T., Misener, S., Schultz, K.M., Millay, M., Ito, A., Liu, T.,
Kamide, C., Agrawal, H., Perlman, H., Qin, G., Kishore, R., Losordo, D.W., 2011.
Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine
activity. Circ. Res. 109, 724–728.
Schachinger, V., Tonn, T., Dimmeler, S., Zeiher, A.M., 2006. Bone-marrow-derived progen-
itor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat. Clin.
Pract. Cardiovasc. Med. 3 (Suppl 1), S23–S28.
Schwach, V., Passier, R., 2016. Generation and puriﬁcation of human stem cell-derived
cardiomyocytes. Differentiation 91, 126–138.
Sumi, T., Tsuneyoshi, N., Nakatsuji, N., Suemori, H., 2008. Deﬁning early lineage speciﬁca-
tion of human embryonic stem cells by the orchestrated balance of canonical Wnt/
beta-catenin, Activin/Nodal and BMP signaling. Development 135, 2969–2979.Surder, D., Manka, R., Lo Cicero, V., Moccetti, T., Ruﬁbach, K., Soncin, S., Turchetto, L.,
Radrizzani, M., Astori, G., Schwitter, J., Erne, P., Zuber, M., Auf Der Maur, C.,
Jamshidi, P., Gaemperli, O., Windecker, S., Moschovitis, A., Wahl, A., Buhler, I., Wyss,
C., Kozerke, S., Landmesser, U., Luscher, T.F., Corti, R., 2013. Intracoronary injection
of bone marrow-derived mononuclear cells early or late after acute myocardial in-
farction: effects on global left ventricular function. Circulation 127, 1968–1979.
Taapken, S.M., Nisler, B.S., Newton, M.A., Sampsell-Barron, T.L., Leonhard, K.A., Mcintire,
E.M., Montgomery, K.D., 2011. Karotypic abnormalities in human induced pluripotent
stem cells and embryonic stem cells. Nat. Biotechnol. 29, 313–314.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem cells frommouse embry-
onic and adult ﬁbroblast cultures by deﬁned factors. Cell 126, 663–676.
Takahashi, M., Li, T.S., Suzuki, R., Kobayashi, T., Ito, H., Ikeda, Y., Matsuzaki, M., Hamano, K.,
2006. Cytokines produced by bone marrow cells can contribute to functional im-
provement of the infarcted heart by protecting cardiomyocytes from ischemic injury.
Am. J. Physiol. Heart Circ. Physiol. 291, H886–H893.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S.,
2007. Induction of pluripotent stem cells from adult human ﬁbroblasts by deﬁned
factors. Cell 131, 861–872.
Tam, P.P., Behringer, R.R., 1997. Mouse gastrulation: the formation of a mammalian body
plan. Mech. Dev. 68, 3–25.
Tendera, M., Wojakowski, W., Ruzyllo, W., Chojnowska, L., Kepka, C., Tracz, W., Musialek,
P., Piwowarska, W., Nessler, J., Buszman, P., Grajek, S., Breborowicz, P., Majka, M.,
Ratajczak, M.Z., Investigators, R., 2009. Intracoronary infusion of bone marrow-de-
rived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients
with acute STEMI and reduced left ventricular ejection fraction: results of random-
ized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Pop-
ulation of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur. Heart J. 30,
1313–1321.
Thery, C., Duban, L., Segura, E., Veron, P., Lantz, O., Amigorena, S., 2002a. Indirect activa-
tion of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3,
1156–1162.
Thery, C., Zitvogel, L., Amigorena, S., 2002b. Exosomes: composition, biogenesis and func-
tion. Nat. Rev. Immunol. 2, 569–579.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S.,
Jones, J.M., 1998. Embryonic stem cell lines derived from human blastocysts. Science
282, 1145–1147.
Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., Hashimoto, H.,
Suzuki, T., Yamashita, H., Satoh, Y., Egashira, T., Seki, T., Muraoka, N., Yamakawa, H.,
Ohgino, Y., Tanaka, T., Yoichi, M., Yuasa, S., Murata, M., Suematsu, M., Fukuda, K.,
2013. Distinct metabolic ﬂow enables large-scale puriﬁcation of mouse and human
pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127–137.
Traverse, J.H., Henry, T.D., Ellis, S.G., Pepine, C.J., Willerson, J.T., Zhao, D.X., Forder, J.R.,
Byrne, B.J., Hatzopoulos, A.K., Penn, M.S., Perin, E.C., Baran, K.W., Chambers, J.,
Lambert, C., Raveendran, G., Simon, D.I., Vaughan, D.E., Simpson, L.M., Gee, A.P.,
Taylor, D.A., Cogle, C.R., Thomas, J.D., Silva, G.V., Jorgenson, B.C., Olson, R.E.,
Bowman, S., Francescon, J., Geither, C., Handberg, E., Smith, D.X., Baraniuk, S., Piller,
L.B., Loghin, C., Aguilar, D., Richman, S., Zierold, C., Bettencourt, J., Sayre, S.L.,
Vojvodic, R.W., Skarlatos, S.I., Gordon, D.J., Ebert, R.F., Kwak, M., Moye, L.A., Simari,
R.D., Cardiovascular Cell Therapy, R., 2011. Effect of intracoronary delivery of autolo-
gous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial in-
farction on left ventricular function: the LateTIME randomized trial. JAMA 306,
2110–2119.
Traverse, J.H., Henry, T.D., Pepine, C.J., Willerson, J.T., Zhao, D.X., Ellis, S.G., Forder, J.R.,
Anderson, R.D., Hatzopoulos, A.K., Penn, M.S., Perin, E.C., Chambers, J., Baran, K.W.,
Raveendran, G., Lambert, C., Lerman, A., Simon, D.I., Vaughan, D.E., Lai, D., Gee, A.P.,
Taylor, D.A., Cogle, C.R., Thomas, J.D., Olson, R.E., Bowman, S., Francescon, J., Geither,
C., Handberg, E., Kappenman, C., Westbrook, L., Piller, L.B., Simpson, L.M., Baraniuk,
S., Loghin, C., Aguilar, D., Richman, S., Zierold, C., Spoon, D.B., Bettencourt, J., Sayre,
S.L., Vojvodic, R.W., Skarlatos, S.I., Gordon, D.J., Ebert, R.F., Kwak, M., Moye, L.A.,
Simari, R.D., Cardiovascular Cell Therapy Research, N., 2012. Effect of the use and
timing of bone marrow mononuclear cell delivery on left ventricular function after
acute myocardial infarction: the TIME randomized trial. JAMA 308, 2380–2389.
Tulloch, N.L., Muskheli, V., Razumova, M.V., Korte, F.S., Regnier, M., Hauch, K.D., Pabon, L.,
Reinecke, H., Murry, C.E., 2011. Growth of engineered human myocardium with me-
chanical loading and vascular coculture. Circ. Res. 109, 47–59.
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., Lotvall, J.O., 2007. Exosome-me-
diated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange
between cells. Nat. Cell Biol. 9, 654–659.
Wollert, K.C., Meyer, G.P., Lotz, J., Ringes-Lichtenberg, S., Lippolt, P., Breidenbach, C., Fichtner,
S., Korte, T., Hornig, B., Messinger, D., Arseniev, L., Hertenstein, B., Ganser, A., Drexler, H.,
2004. Intracoronary autologous bone-marrow cell transfer after myocardial infarction:
the BOOST randomised controlled clinical trial. Lancet 364, 141–148.
Wollert, K.C., Drexler, H., 2005. Clinical applications of stem cells for the heart. Circ. Res.
96, 151–163.
Wu, S.M., Fujiwara, Y., Cibulsky, S.M., Clapham, D.E., Lien, C.L., Schultheiss, T.M., Orkin,
S.H., 2006. Developmental origin of a bipotential myocardial and smooth muscle
cell precursor in the mammalian heart. Cell 127, 1137–1150.
Xu, X.Q., Zweigerdt, R., Soo, S.Y., Ngoh, Z.X., Tham, S.C., Wang, S.T., Graichen, R., Davidson,
B., Colman, A., Sun,W., 2008. Highly enriched cardiomyocytes from human embryon-
ic stem cells. Cytotherapy 10, 376–389.
Xu, Q., Seeger, F.H., Castillo, J., Iekushi, K., Boon, R.A., Farcas, R., Manavski, Y., Li, Y.G.,
Assmus, B., Zeiher, A.M., Dimmeler, S., 2012. Micro-RNA-34a contributes to the im-
paired function of bone marrow-derived mononuclear cells from patients with car-
diovascular disease. J. Am. Coll. Cardiol. 59, 2107–2117.
Yamaguchi, T.P., 2001. Heads or tails: Wnts and anterior-posterior patterning. Curr. Biol.
11, R713–R724.
40 R. Duelen, M. Sampaolesi / EBioMedicine 16 (2017) 30–40Yang, X., Pabon, L., Murry, C.E., 2014. Engineering adolescence: maturation of human plu-
ripotent stem cell-derived cardiomyocytes. Circ. Res. 114, 511–523.
Ye, L., Chang, Y.H., Xiong, Q., Zhang, P., Zhang, L., Somasundaram, P., Lepley, M., Swingen,
C., Su, L., Wendel, J.S., Guo, J., Jang, A., Rosenbush, D., Greder, L., Dutton, J.R., Zhang, J.,
Kamp, T.J., Kaufman, D.S., Ge, Y., Zhang, J., 2014. Cardiac repair in a porcine model of
acute myocardial infarction with human induced pluripotent stem cell-derived car-
diovascular cells. Cell Stem Cell 15, 750–761.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J.,
Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, I., Thomson, J.A., 2007. Induced plurip-
otent stem cell lines derived from human somatic cells. Science 318, 1917–1920.
Zhang, J., Wilson, G.F., Soerens, A.G., Koonce, C.H., Yu, J., Palecek, S.P., Thomson, J.A., Kamp,
T.J., 2009. Functional cardiomyocytes derived from human induced pluripotent stem
cells. Circ. Res. 104, e30–e41.
Zhang, Q., Jiang, J., Han, P., Yuan, Q., Zhang, J., Zhang, X., Xu, Y., Cao, H., Meng, Q., Chen, L.,
Tian, T., Wang, X., Li, P., Hescheler, J., Ji, G., Ma, Y., 2011. Direct differentiation of atrialand ventricular myocytes from human embryonic stem cells by alternating retinoid
signals. Cell Res. 21, 579–587.
Zhao, T., Zhang, Z.N., Rong, Z., Xu, Y., 2011. Immunogenicity of induced pluripotent stem
cells. Nature 474, 212–215.
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K., Ding, S., 2010.
Reprogramming of human primary somatic cells by OCT4 and chemical compounds.
Cell Stem Cell 7, 651–655.
Zimmermann,W.H., Didie, M., Wasmeier, G.H., Nixdorff, U., Hess, A., Melnychenko, I., Boy,
O., Neuhuber, W.L., Weyand, M., Eschenhagen, T., 2002. Cardiac grafting of
engineered heart tissue in syngenic rats. Circulation 106, I151–I157.
Zimmermann,W.H., Melnychenko, I., Wasmeier, G., Didie, M., Naito, H., Nixdorff, U., Hess,
A., Budinsky, L., Brune, K., Michaelis, B., Dhein, S., Schwoerer, A., Ehmke, H.,
Eschenhagen, T., 2006. Engineered heart tissue grafts improve systolic and diastolic
function in infarcted rat hearts. Nat. Med. 12, 452–458.
